300 related articles for article (PubMed ID: 28535155)
1. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3B is an enzymatic source of mutation in breast cancer.
Burns MB; Lackey L; Carpenter MA; Rathore A; Land AM; Leonard B; Refsland EW; Kotandeniya D; Tretyakova N; Nikas JB; Yee D; Temiz NA; Donohue DE; McDougle RM; Brown WL; Law EK; Harris RS
Nature; 2013 Feb; 494(7437):366-70. PubMed ID: 23389445
[TBL] [Abstract][Full Text] [Related]
3. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
4. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB.
Periyasamy M; Singh AK; Gemma C; Farzan R; Allsopp RC; Shaw JA; Charmsaz S; Young LS; Cunnea P; Coombes RC; Győrffy B; Buluwela L; Ali S
Oncogene; 2021 Feb; 40(6):1077-1090. PubMed ID: 33323971
[TBL] [Abstract][Full Text] [Related]
5. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells.
Periyasamy M; Singh AK; Gemma C; Kranjec C; Farzan R; Leach DA; Navaratnam N; Pálinkás HL; Vértessy BG; Fenton TR; Doorbar J; Fuller-Pace F; Meek DW; Coombes RC; Buluwela L; Ali S
Nucleic Acids Res; 2017 Nov; 45(19):11056-11069. PubMed ID: 28977491
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
Buisson R; Lawrence MS; Benes CH; Zou L
Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
[TBL] [Abstract][Full Text] [Related]
7. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
[TBL] [Abstract][Full Text] [Related]
8. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
9. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
10. The roles of APOBEC3B in gastric cancer.
Zhang J; Wei W; Jin HC; Ying RC; Zhu AK; Zhang FJ
Int J Clin Exp Pathol; 2015; 8(5):5089-96. PubMed ID: 26191203
[TBL] [Abstract][Full Text] [Related]
11. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
[TBL] [Abstract][Full Text] [Related]
12. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
Chaudhary P; Sharma R; Sahu M; Vishwanatha JK; Awasthi S; Awasthi YC
J Biol Chem; 2013 Jul; 288(28):20532-46. PubMed ID: 23733185
[TBL] [Abstract][Full Text] [Related]
14. Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
Green AM; Budagyan K; Hayer KE; Reed MA; Savani MR; Wertheim GB; Weitzman MD
Cancer Res; 2017 Sep; 77(17):4579-4588. PubMed ID: 28655787
[TBL] [Abstract][Full Text] [Related]
15. Genetic vulnerabilities upon inhibition of DNA damage response.
Wang C; Tang M; Chen Z; Nie L; Li S; Xiong Y; Szymonowicz KA; Park JM; Zhang H; Feng X; Huang M; Su D; Hart T; Chen J
Nucleic Acids Res; 2021 Aug; 49(14):8214-8231. PubMed ID: 34320214
[TBL] [Abstract][Full Text] [Related]
16. The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
Serebrenik AA; Argyris PP; Jarvis MC; Brown WL; Bazzaro M; Vogel RI; Erickson BK; Lee SH; Goergen KM; Maurer MJ; Heinzen EP; Oberg AL; Huang Y; Hou X; Weroha SJ; Kaufmann SH; Harris RS
Clin Cancer Res; 2020 Jul; 26(13):3397-3407. PubMed ID: 32060098
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells.
Kim JY; Choi HE; Lee HH; Shin JS; Shin DH; Choi JH; Lee YS; Lee KT
Oncol Rep; 2015 May; 33(5):2639-47. PubMed ID: 25812484
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
19. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
20. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
